Strs Ohio acquired a new position in shares of Zogenix, Inc. (NASDAQ:ZGNX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,000 shares of the company’s stock, valued at approximately $55,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Zogenix by 18.1% during the third quarter. Vanguard Group Inc. now owns 2,070,386 shares of the company’s stock worth $102,691,000 after acquiring an additional 318,010 shares in the last quarter. Emory University raised its stake in Zogenix by 0.8% during the fourth quarter. Emory University now owns 57,822 shares of the company’s stock worth $2,108,000 after acquiring an additional 448 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Zogenix by 4.6% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 21,006 shares of the company’s stock worth $766,000 after acquiring an additional 933 shares in the last quarter. Eversept Partners LP raised its stake in Zogenix by 34.4% during the fourth quarter. Eversept Partners LP now owns 563,429 shares of the company’s stock worth $20,543,000 after acquiring an additional 144,150 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Zogenix by 45.4% during the fourth quarter. Rhumbline Advisers now owns 56,857 shares of the company’s stock worth $2,073,000 after acquiring an additional 17,753 shares in the last quarter.
In related news, Director Cam L. Garner sold 5,625 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $50.00, for a total value of $281,250.00. Following the sale, the director now directly owns 4,756 shares in the company, valued at $237,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cam L. Garner sold 15,250 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $50.00, for a total value of $762,500.00. The disclosure for this sale can be found here. Insiders sold 119,078 shares of company stock worth $6,248,177 over the last quarter. 4.40% of the stock is currently owned by company insiders.
ZGNX has been the subject of several research analyst reports. Leerink Swann set a $48.00 target price on Zogenix and gave the stock an “outperform” rating in a research note on Tuesday, April 9th. Mizuho reaffirmed a “buy” rating and issued a $69.00 price objective on shares of Zogenix in a research note on Tuesday, March 19th. LADENBURG THALM/SH SH set a $50.00 price objective on Zogenix and gave the company a “buy” rating in a research note on Tuesday, April 9th. Guggenheim initiated coverage on Zogenix in a research note on Friday, February 22nd. They issued a “buy” rating and a $70.00 price objective for the company. Finally, Svb Leerink lowered their price objective on Zogenix from $60.00 to $48.00 and set an “outperform” rating for the company in a research note on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $61.17.
Zogenix stock opened at $37.48 on Thursday. Zogenix, Inc. has a 1 year low of $33.43 and a 1 year high of $62.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.12 and a quick ratio of 9.12. The company has a market capitalization of $1.59 billion, a PE ratio of -11.60 and a beta of 1.96.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. On average, sell-side analysts predict that Zogenix, Inc. will post -3.61 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Macon Daily and is owned by of Macon Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://macondaily.com/2019/05/16/strs-ohio-acquires-new-stake-in-zogenix-inc-zgnx.html.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
See Also: What Are Treasury Bonds?
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.